چکیده (انگلیسی):

Objective/Background: Cytomegalovirus (CMV) causes significant morbidity and mortality in
CMV seropositive patients undergoing umbilical cord blood transplants (UCBT). Our study aimed
to describe the incidence of CMV reactivation and burden of disease, as well as the tolerability
of an intensive prevention strategy as compared to historical prevention.
Methods: This was a retrospective chart review of 33 CMV seropositive patients that underwent
UCBT. The intensive prevention strategy in UCBT consisted of ganciclovir 5 mg/kg/d intravenously
or valganciclovir 900 mg by mouth daily initiated at the beginning of the conditioning
regimen until Day
2. Then from Day
1 to Day +100, patients received valacyclovir 2 g by
mouth three times daily, and from Day +101 to Day +365, acyclovir 800 mg by mouth twice
daily. Historical standard prevention was acyclovir 800 mg by mouth twice daily initiated at
the beginning of the conditioning regimen until Day +365.
Results: Thirty-three patients were included from 2008 to 2014. There were no differences in
the adverse effects experienced between the two regimens (p = .4).